Project Achoo: A Practical Model and Application for COVID-19 Detection from Recordings of Breath, Voice, and Cough

The COVID-19 pandemic created a significant interest and demand for infection detection and monitoring solutions. In this paper we propose a machine learning method to quickly triage COVID-19 using recordings made on consumer devices. The approach combines signal processing methods with fine-tuned deep learning networks and provides methods for signal denoising, cough detection and classification. We have also developed and deployed a mobile application that uses symptoms checker together with voice, breath and cough signals to detect COVID-19 infection. The application showed robust performance on both open sourced datasets and on the noisy data collected during beta testing by the end users

A Vacuum-driven Origami “Magic-ball” Soft Gripper

Soft robotics has yielded numerous examples of soft grippers that utilize compliance to achieve impressive grasping performances with great simplicity, adaptability, and robustness. Designing soft grippers with substantial grasping strength while remaining compliant and gentle is one of the most important challenges in this field. In this paper, we present a light-weight, vacuum-driven soft robotic gripper made of an origami “magic-ball” and a flexible thin membrane. We also describe the design and fabrication method to rapidly manufacture the gripper with different combinations of lowcost materials for diverse applications. Grasping experiments demonstrate that our gripper can lift a large variety of objects, including delicate foods, heavy bottles, and other miscellaneous items. The grasp force on 3D-printed objects is also characterized through mechanical load tests. The results reveal that our soft gripper can produce significant grasp force on various shapes using negative pneumatic pressure (vacuum). This new gripper holds the potential for many practical applications that require safe, strong, and simple graspingUnited States. Defense Advanced Research Projects Agency (award number FA8650-15-C-7548)National Science Foundation (U.S.) (award number 1830901)Wyss Institute for Biologically Inspired EngineeringJD.co

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment